Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara) today announced that it has resolved at the Board of Directors meeting held today to revise the year-end dividend forecast for the fiscal year ending March 2021 as follows:

1. Revision of dividend forecast
   Revision of the year-end dividend forecast for the FY ending March 2021 (the 73rd)

   	Dividend per share
   -	Interim	Year-end	Full Year
   Previous Forecast (announced on May 12, 2020)	¥22.50	¥22.50	¥45.00
   Revised Forecast	-	¥27.50	¥50.00
   Actual amount for the current fiscal year	¥22.50	-	-
   Actual amount for the previous fiscal year (year ended March, 2020)	¥22.50	¥22.50	¥45.00

2. Reasons for the revision
   We position the return of the Company’s profits to its shareholders as one of our important management policies, and make it our basic policy to strive to maintain stable dividends over the medium to long term and to distribute results according to our business performance.
   In the fiscal year ending March 2021, the sales of Opdivo Intravenous Infusion significantly exceeded the initial forecast, and loyalty and other revenues also exceeded the initial forecast due to the conclusion of the license agreement on PD-L1 antibody-related patents with Roche. As we revised our consolidated financial forecasts upward on October 29, 2020 and February 1, 2021, the revenues have been steadily increasing.
   Based on the above policy and considering the full-year earnings forecast and financial condition comprehensively, we have decided to revise the year-end dividend forecast announced last time to 27.50 yen, an increase of 5 yen per share. As a result, the annual dividend, including the interim dividend, will be 50 yen per share.